---

A review on macrocyclic kinase inhibitors in clinical trials

Full Text PDF

---

Review Article

Author Details : Alemu Tadesse Feroche*, Frehiwot Beyene Woselassie

Volume : 11, Issue : 2, Year : 2024

Article Page : 147-152

https://doi.org/10.18231/j.ijpca.2024.020

Suggest article by email

Get Permission

Abstract

Macrocyclic kinase inhibitors have high binding affinity and selectivity towards a variety of kinases including mammalian target of rapamycin complex 1/2, janus kinases/ Fms like tyrosine kinase, cyclin-dependent kinases and anaplastic lymphoma kinase1. Recently, few macrocyclic kinase inhibitors have entered clinical trial for treatment different types of cancers including leukemia, non-small cell lung cancer, myelofibrosis, breast cancer, glioblastoma and lymphoma. Of them, ridaforomilus has completed Phase III clinical trial and is waiting to be approved for treatment of breast cancer and advanced leukemia. Pacritinib is also currently being tested in phase III clinical trial for treatment of myelofibrosis and, loratinib is being evaluated for advanced ALK gene positive nonsmall cell lung carcinoma. The broad-spectrum cyclin-dependent kinases inhibitor, TGO2, has also entered phase II clinical trial for treatment of glioblastoma and advanced leukemia.

Keywords: Macrocyclic kinase inhibitors, Protein kinase, mTOR, CDK, ALK, JAK/FLT3

How to cite : Feroche A T, Woselassie F B, A review on macrocyclic kinase inhibitors in clinical trials. Int J Pharm Chem Anal 2024;11(2):147-152

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.